Takeda and Noile-Immune Biotech Collaborate to Advance Next Generation CAR-T Cell Therapy Effective for Solid Tumors

By JPN, Pharmaceutical

Takeda and Noile-Immune Biotech Collaborate to Advance Next Generation CAR-T Cell Therapy Effective for Solid Tumors.

Osaka and Tokyo, Japan, September 4, 2017 – Takeda Pharmaceutical Company Limited (TSE: 4502) and Noile-Immune Biotech Inc. announced that they have entered into a collaboration to develop next generation chimeric antigen receptor T cell therapy (CAR-T). The next generation CAR-T cell therapy was developed by Professor Koji Tamada at Yamaguchi University and Noile-Immune has exclusive license for this platform technology.

https://www.takeda.com/newsroom/newsreleases/2017/takeda-and-noile-immune-biotech-collaborate–to-advance-next-generation-car-t-cell-therapy-effective-for-solid-tumors3/

More from tokioX :

  1. 🍀Proposed Acquisition of Shire plc by Takeda
  2. 💊Takeda Statement Regarding Improved Proposal for Shire plc
  3. 💊Takeda Statement Regarding Shire
  4. 💉Takeda’s Zika Vaccine Candidate Receives U.S. FDA Fast Track Designation
  5. 💊Takeda and Denali Therapeutics Collaborate to Develop and Commercialize Therapies for Neurodegenerative Diseases
  6. 💊FDA PHARMA today
  7. 💊Takeda and HemoShear Therapeutics Enter into Exclusive Drug Discovery Partnership in Liver Diseases